Tilray | TRLY - Interest Expense On Debt

Stock Price
9.48
Daily Change
-0.03 -0.32%
Monthly
-7.60%
Yearly
977.27%
Q1 Forecast
9.24

Tilray reported $6.7M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.





Interest Expense On Debt Change Date
Akebia Therapeutics 364.15M 18.56M Sep/2025
Alaunos Therapeutics USD 0 0 Dec/2023
Aurora Cannabis CAD 2.22M 442K Sep/2025
Avita Medical AUD 1.25M 100K Jun/2025
Canopy Growth CAD 8.8M 938K Sep/2025
Cronos Group USD 0 7K Sep/2024
Dianthus Therapeutics USD 4.44M 263K Sep/2024
Divis Laboratories Ltd INR 60M 30M Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
IQVIA Holdings USD 193M 4M Dec/2025
Knight Therapeutics CAD 2.37M 6K Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Organon & Co USD 128M 3M Sep/2025
Revvity USD 23.51M 742K Dec/2025
Tectonic Therapeutic USD 277M 276.98M Sep/2025
Tilray USD 6.7M 2.73M Jun/2025
Viatris USD 119.6M 0 Dec/2025
Xeris Pharmaceuticals USD 7.27M 92K Sep/2025